Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
William Blair sets $226 price target for Revolution Medicines (RVMD) following Rasonque approval and major oncology expansion plans.
Share
Why It Matters
Revolution Medicines stock has gone up a lot this year. An analyst thinks the company's new cancer medicine and growth plans mean the stock could go even higher.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.